Acute Hyperglycemia Associated with Short-Term Use of Atypical Antipsychotic Medications
- 382 Downloads
The prevalence of metabolic disturbances associated with long-term use of antipsychotic medications has been widely reported in the literature. The use of atypical antipsychotics for the treatment of delirium in the intensive care unit (ICU) has gained popularity due to a lower potential for adverse effects compared with conventional antipsychotics. However, current studies evaluating safety and efficacy of antipsychotics in the ICU setting do not include metabolic parameters as a potential adverse effect that requires monitoring. It is thought that long-term adverse effects of antipsychotics may be out of context for the intensive care setting. A literature review was conducted to investigate the prevalence of acute hyperglycemia associated with short-term use of antipsychotics, with the purpose of reviewing evidence that hyperglycemia may occur even with short-term use of atypical antipsychotics. A MEDLINE search for acute hyperglycemia from short-term use of antipsychotics resulted in studies involving animal models and healthy volunteers. These studies indicate that acute hyperglycemia may occur after short-term treatment. A review of the literature shows preliminary evidence to suggest that atypical antipsychotics impact glucose sensitivity and induce insulin resistance even after a single dose. Although no studies have been conducted evaluating the impact of hyperglycemia in critically ill patients from the short-term use of atypical antipsychotics for the treatment of delirium, the potential to affect clinical outcomes exist and warrants further research in this area.
KeywordsHaloperidol Clozapine Risperidone Olanzapine Quetiapine
The authors would like to acknowledge John Papadopoulos, B.S., Pharm.D., FCCM, BCNSP for his assistance with reviewing and commenting on a draft of the manuscript.
Conflict of interest statement
T.V. Liao and S.V. Phan have no conflict of interest to report. No financial assistance was used to assist in the preparation of this manuscript. This work has not been presented previously.
- 1.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.Google Scholar
- 7.Miller RR, Shintani A, Girard TD, et al. Delirium predicts extubation failure. Proc Am Thorac Soc. 2006;3:A42.Google Scholar
- 13.Page V, Gough K. Management of delirium in the intensive care unit. Brit J Hosp Med (Lond). 2010;71(7):372–6.Google Scholar
- 16.Haloperidol. DRUGDEX® System (version 5.1) [Intranet], 17 Dec 2013. Greenwood Village: Thomson Reuters (Healthcare) Inc.Google Scholar
- 28.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.Google Scholar
- 46.Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand. 2002;105(3):235–6 (discussion 236–7).Google Scholar
- 53.Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, et al. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95:118–25.Google Scholar
- 56.Mac Sweeney R, Barber V, Page V, et al. A national survey of the management of delirium in UK intensive care units. QJM. 2010;103:243–51.Google Scholar
- 57.NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.Google Scholar
- 58.American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S11–63.Google Scholar
- 59.Moghissi ES, Korytkowski MT, DiNardo M, American Association of Clinical Endocrinologists, American Diabetes Association, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31.Google Scholar
- 63.Broderick JP, Diringer MN, Hill MD, et al.; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke. 2007;38:1072–5.Google Scholar